menu
    • menu
    [{"orgOrder":0,"company":"Nucleai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Naratuximab Emtansine","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nucleai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nucleai \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nucleai \/ Not Applicable"},{"orgOrder":0,"company":"Nucleai","sponsor":"Adlai Nortye","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Buparlisib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nucleai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nucleai \/ Nucleai","highestDevelopmentStatusID":"10","companyTruncated":"Nucleai \/ Nucleai"}]

    Find Clinical Drug Pipeline Developments & Deals by Nucleai

    Menu

    Nucleai

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nucleai

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Nucleai

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Adlai Nortye

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trial...

                            Details : The collaboration aims to focus on identifying subjects that could derive benefit from AN2025 (buparlisib) treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.

                            Brand Name : AN2025

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 31, 2023

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Adlai Nortye

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nucleai

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Nucleai

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naratuximab Emtansine,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nucleai to Publish Pathology-based Data at ASCO 2022 for Phase 2 Research of the Most Common Type of Non-Hodgk...

                            Details : A phase 2 study evaluated the efficacy of Debio 1562 (naratuximab emtansine), an anti-CD37 ADC, in combination with rituximab, in patients with R/R DLBCL. Deep learning models were used to extract spatial features from digitized slides stained with CD37 ...

                            Brand Name : Debio 1562

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 04, 2022

                            Lead Product(s) : Naratuximab Emtansine,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth